PRESS RELEASE
FOR IMMEDIATE RELEASE:
February 23, 2008
Contact: Chuck Hilger, CMG
chilger2@earthlink.net
CMG Now Offering Suboxone
Colonial Management Group (CMG), with 54 opiate addiction treatment centers located throughout the United States, announced that as of January 1, 2008 all of their facilities are now offering Buprenorphine (Brand name Suboxone) in addition to their Methadone Maintenance Program.
Suboxone (Buprenorphine/Naloxone) received approval by the FDA on October 8, 2002. It is state of the art medication to treat the medical condition of Opioid addiction. It is improving the quality of life for patients in recovery and giving them hope, dignity, and the ability to have a normal life again.
|
Buprenorphine Maintenance Versus Placebo or Methadone
The Cochrane Review (pdf)
Interesting Description of how Buprenorphine Works
How Buprenorphine Works (pdf)
Gracer Medical Group
Richard I. Gracer, M.D.
|
Here is some GREAT information from the SAMHSA Website on Buprenorphine....
About Buprenorphine Therapy
In October 2002, the FDA approved buprenorphine monotherapy product, Subutex®, and a buprenorphine/naloxone combination product, Suboxone®, for use in opioid addiction treatment. The combination product is designed to decrease the potential for abuse by injection. Subutex® and Suboxone® are currently the only Schedule III, IV, or V medications to have received FDA approval for this indication.
Note that aside from Subutex® and Suboxone®, other forms of buprenorphine, e.g., Buprenex®, are not approved for treatment of opioid addiction.
The FDA approval of these buprenorphine formulations does not affect the status of other medication-assisted opioid addiction treatments, such as methadone and LAAM (levo-alpha-acetyl-methadol). As indicated in Title 42 Code of Federal Regulations Part 8 (42 CFR Part 8), these treatments can only be dispensed, and only in the context of an Opioid Treatment Program. Also, neither the approval of Subutex® and Suboxone®, nor the provisions of DATA 2000, affect the use of other Schedule III, IV, or V medications, such as codeine, that are not approved for the treatment of addiction.
Lastly, note that aside from Subutex® and Suboxone®, other forms of buprenorphine, e.g., Buprenex®, are not approved for treatment of opioid addiction.
[READ MORE]
BUPRENORPHINE PHYSICIAN LOCATOR
http://buprenorphine.samhsa.gov/bwns_locator/index.html
**Naabt.org now has an improved search feature of the SAMHSA list of certified prescribers. It now includes proximity searching that automatically displays certified prescribers sorted from the closest to the zip code a patient entered. This helps people near geographical borders, and approximates how far one would need to travel for treatment.
Click the “Patient / Doctor Connection” button on any page at naabt.org or click the link below to try it:
New Physician locator (SAMHSA data):
http://naabt.org/patient_dr_connection.cfm
FREQUENTLY ASKED QUESTIONS
http://buprenorphine.samhsa.gov/faq.html
PUBLICATIONS
http://buprenorphine.samhsa.gov/publications.html
ADDITIONAL RESOURCES
http://buprenorphine.samhsa.gov/otherlinks.html
|
|
>
